Boston Scientific Corporation (BSX) Earnings Call Analysis

NYSE · Healthcare · Medical Devices

Earnings Reports

• Boston Scientific (BSX) Q2 2026: Watchman Drops to -7% in H2, Pivots Growth Mix for 2027
  July 29, 2026
• Boston Scientific (BSX) Q4 2025: EP Franchise Soars 35%, Diversification Drives 2026 Visibility
  June 15, 2026
• Boston Scientific (BSX) Q1 2026: Guidance Cut as EP and Watchman Growth Slows, $2B Buyback Signals Capital Confidence
  April 22, 2026
• Boston Scientific (BSX) Q3 2025: Margin Expansion Hits 100bps as Mix and Tariff Offsets Drive Resilience
  October 22, 2025
• Boston Scientific (BSX) Q2 2025: PFA Portfolio Drives Double-Digit Cardiology Growth, Expands Competitive Moat
  July 23, 2025
• Boston Scientific (BSX) Q1 2025: Cardiology Soars 31%, Offsetting $200M Tariff Headwind
  July 01, 2025
• Boston Scientific (BSX) Q3 2024: EP Sales Surge 177% as PFA Adoption Outpaces Expectations
  October 23, 2024
• Boston Scientific (BSX) Q2 2024: EP Sales Surge 125% as PFA Adoption Fuels Guidance Raise
  July 24, 2024
• Boston Scientific (BSX) Q1 2024: Electrophysiology Surges 72%, Raising Full-Year Growth Outlook
  April 24, 2024
• Boston Scientific (BSX) Q4 2023: Electrophysiology Surges 43% as Farapulse Approval Unlocks Next Growth Leg
  January 31, 2024

Browse all companies